Glucocorticosteroids are used frequently in the management of patients with rheumatoid arthritis. Data supporting their efficacy and safety are still meagre. Glucocorticosteroids may be used systemically with different routes of administration (oral, i.m. and i.v.), in different doses and for different periods of time. The effectiveness of glucocorticosteroids in reducing inflammation in the short term has been shown for oral treatment in a dose of 7.5 mg prednisolone daily or more, for i.m. pulses (120 mg methylprednisolone every 4 weeks) and for i.v. methylprednisolone pulses. For longer periods of treatment, the evidence suggesting effectiveness of low-dose oral glucocorticosteroids is more limited. Some data suggest that different regimens of glucocorticosteroids may retard the development of erosions in patients with rheumatoid arthritis. The toxicity of short-term treatment is relatively low. For long-term treatment, the development of osteoporosis is a serious problem. Concomitant therapy with either calcitriol or bisphosphonates may reduce this risk.
A previous contribution to the disease-modifying drugs all cell types. The activated hormone-receptor complex is bound to specific sites within DNA in the nucleus, series in this journal, addressing the use of methotrexate in rheumatoid arthritis (RA), notes in its introduction causing modulation of specific genes. Favourable effects of glucocorticosteroids in patients the wealth of articles on this subject in the recent literature [1] . For glucocorticosteroids, the situation is with rheumatoid arthritis may be explained either by their general anti-inflammatory and immunomodulatory rather different. In a recent meta-analysis studying their moderate-term effectiveness, only nine studies could be effects or, hypothetically, by more disease-specific mechanisms. included: four comparing glucocorticosteroids to placebo and five to other active drugs, the authors being General effects [5] unable to evaluate radiographic outcomes [2] . This Glucocorticosteroids have effects on different cell types paper attempts to summarize the effects of glucocorticoinvolved in the inflammatory process. Proliferation, steroids on disease activity and on the progression of differentiation, and function of macrophages and joint damage in RA. Some emphasis will be given to fibroblasts are inhibited by glucocorticosteroids. Effects the most recent contributions to the literature [3, 4] .
include the inhibition of the production and release of The toxicity of glucocorticosteroids will also be discuscytokines such as interleukin-1, interleukin-6 and sed briefly.
tumour necrosis factor alpha. They also influence the production of arachidonic acid metabolites, including
Mode of action of glucocorticosteroids both prostaglandins and leukotrienes. Induction of inhibitors of phospholipase A2, like lipocortin, may be Comprehensive reviews have been published on this central to this effect. They also decrease expression of topic [5] . The basic mechanism of action involves passive cyclooxygenase type 2. Glucocorticosteroids further diffusion of free circulating glucocorticosteroids through inhibit many pro-inflammatory responses of endothe plasma membrane and subsequent binding to specific thelial cells. intracellular cytoplasmic receptors, which are present in Treatment with glucocorticosteroids causes redistribution of lymphocytes, resulting in circulating lymph-mechanisms. B cells and plasma cells are less affected, Effects on disease activity high doses of glucocorticosteroids being necessary for suppression of immunoglobulin production.
Oral glucocorticosteroids Short-term use. Recently, two meta-analyses of the Disease-specific effects effectiveness of low-dose glucocorticosteroids have been Chikanza et al. [6 ] have found that the hypothalamicpublished [2, 8] . One of them addresses the short-term pituitary-adrenal axis of patients with RA responds less (1-2 weeks) efficacy of low-dose prednisone in RA [8] . to surgical stress than that in patients with osteoarthritis
The authors conclude that prednisolone has a marked or osteomyelitis. The numbers studied so far have been symptomatic effect when used in doses of 15 mg daily few. Their results suggests that patients with RA may or less. Saag et al. [2] studied the intermediate term have a defective hypothalamic regulation of the pituit-(3 months or longer) efficacy. The results indicate that ary-adrenal axis. As a consequence, these patients could glucocorticosteroids, in doses equivalent to up to be more prone to develop chronic arthritis. These inter-15 mg/day prednisolone and in the first 6 months of esting data have as yet not been confirmed by others [7] . their use, are more effective than placebo in improving the number of tender and swollen joints and the erythrocyte sedimentation rate. The size of the effect seems to
How are glucocorticosteroids used in be similar to that of traditional second-line agents.
rheumatoid arthritis?
However, the small number of studies that could be included in the meta-analysis, the small number of Over the years, glucocorticosteroids have been employed patients included in most studies, and differences in several ways. In this paper, the intra-articular use of between these studies with respect to the precise dose glucocorticosteroids is not discussed. For the systemic use of these drugs, different regimens can be classified used, limit the conclusions that can be drawn from this according to the route of administration, the dose used meta-analysis. and the expected duration of treatment ( Table 1) .
The use of oral low-dose glucocorticosteroids as Glucocorticosteroids are used either as a single agent or bridge therapy has been studied in only two placeboin combination with other anti-rheumatic drugs. In controlled trials, which together represent a major part short-term (duration of use <1 yr) regimens, treatment of the intermediate term meta-analysis mentioned above is often aimed at controlling symptoms in periods of [9, 10] . Harris et al. [9] added prednisone (5 mg/day) high disease activity either with unchanged background to other drugs including non-steroidal anti-inflammatory anti-rheumatic therapy or while awaiting the effects of drugs and constant doses of gold salts or penicillamine newly started other disease-modifying drugs. This kind over 24 weeks. Nearly all variables related to disease of use is commonly referred to as bridge therapy. In activity failed to show a significant difference between patients in whom other drugs have failed to control the the prednisone (n = 18) and placebo (n = 16) treated arthritic symptoms sufficiently, due to inadequate effipatients. After abrupt cessation of prednisone at week cacy or to the occurrence of side-effects, glucocortico-24, disease activity markedly exacerbated, inflammation steroids are used for prolonged periods of time.
being significantly worse in the prednisone group at Glucocorticosteroids may also be prescribed specifically week 36. The efficacy of 10 mg/day prednisone was to prevent progression of joint damage as assessed by studied in 40 patients who started treatment with i.m. radiological scores. In the recent literature, two different gold salts by van Gestel et al. [10] . Rapid improvement approaches have been presented. Kirwan [3] proposed was observed in the prednisone-treated patients (n =20), long-term treatment with low-dose oral glucocorticosthe difference with the placebo-treated patients (n = 20) teroids in addition to other anti-rheumatic treatments.
already being significant after 1 week. Responses to Boers et al. [4] have studied the effects of intensive early prednisone were noticed in 60% of patients only. After combination therapy including short-term high-dose gradual tapering of prednisone, a rebound deterioration glucocorticosteroids.
was observed in the majority of the responders. A much larger (n = 155) double-blind randomized trial was recently published by Boers et al. [4] . They compared the combination of sulphasalazine (2 g/day), [3, [11] [12] [13] [14] [15] [16] [17] [18] was seen in the combination therapy prednisolonetreated patients who had a clear advantage over the *Details of these studies are mentioned in the text. †Low dose defined as 15 mg/day prednisolone equivalent or less.
single treatment group. This advantage was lost after withdrawal of the glucocorticosteroids. The magnitude of the follow-up of 2 yr, these advantages gradually disappeared. of the effect was greater than in the study by van Gestel
Minimally effective dose? The dose-response relationet al.
[10] who did not initially use high-dose glucocortship has not been studied well for oral glucocorticosteroicosteroids. With similar baseline values, the combined ids. Combining the results from various studies suggests disease activity score (DAS) improved with 2.1 at week that the minimally effective dose lies somewhere between 28 in the high-dose study and with 1.6 at week 12 in 5 and 10 mg prednisolone daily [3, 4, 9, 10] . Individual the low-dose study. Responses to the combined treatpatients may, of course, respond to lower doses or be ment were observed in 72% of patients. Flares after in need of higher doses. withdrawal of glucocorticosteroids were less of a problem than in previous studies.
Intramuscular glucocorticosteroids Long-term use: glucocorticosteroids as a single agent.
Intramuscular methylprednisolone pulse treatment Soon after the introduction of glucocorticosteroids in (120 mg three times at 4-weekly intervals) has been the treatment of rheumatoid arthritis, large randomized shown to be an effective bridge therapy when initiating trials were performed by the Empire Rheumatism chrysotherapy [19] . An advantage of this regimen over Council ( ERC ) and the Medical Research Council the oral equivalent already discussed before [10] is the (MRC ) in co-operation with the Nuffield Foundation lack of a rebound deterioration. This is probably due [11] [12] [13] [14] [15] . The trials were designed to compare the effects to the slow fall in serum levels by using an i.m. depot of glucocorticosteroids with those of aspirin. In the regimen. No clear advantage of a similar treatment initial trials, cortisone was used in doses equivalent to could be shown in the initial phase of sulphasalazinẽ 15 mg prednisolone daily. The ERC trial included treatment [20] . The reason for the apparent discrepancy patients with variable disease duration [11, 12] , while between the responses to i.m. methylprednisolone pulses the MRC trial involved patients with early disease in patients starting gold salts or sulphasalazine has not [13] [14] [15] . These early studies were unable to show clear been clarified. Possibly, glucocorticosteroids may interbenefits of glucocorticosteroids over aspirin in the long fere with the efficacy in the initial phase of sulphasalazine term, although initial responses were better in the cortistreatment. Bridge therapy with i.m. glucocorticosteroids one-treated patients. A study initiated some years later has not been studied with other second-line antialso in patients with early disease used prednisolone rheumatic drugs. in a comparison with aspirin or phenylbutazone.
Intravenous glucocorticosteroids Prednisolone was started at 20 mg/day and gradually tapered to 10 mg/day after 2 and 3 yr [16, 17]. The
Various regimens of i.v. methylprednisolone pulse treatprednisolone-treated patients experienced a rapid ments have been published in the past two decades and improvement both in clinical and biochemical indices of this topic has been reviewed recently [21] . Doses in the disease activity, which was statistically significantly different studies vary between 40 and 1000 mg. Some better than in the aspirin or phenylbutazone group. The have studied the effects of a single infusion, while others improvement was maintained in the long term.
have employed repeated administrations (three on conMore recently, Van Schaardenburg et al. [18] comsecutive days, three on alternate days or monthly for 6 pared disease activity in 28 active elderly-onset RA months). All studies have involved only relatively small patients treated with prednisone (15 mg daily during 1 numbers of patients [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . In general, these studies month, followed by a tapering scheme according to have shown beneficial effects on disease activity paraclinical success) with 28 patients receiving chloroquine meters including both clinical and biochemical variables in a prospective randomized study with a follow-up of related to the acute-phase response. Sustained responses 2 yr. Functional capacity and disease activity improved have been observed in some patients, especially for the significantly, but similarly in both groups, except for a clinical variables. The optimal dose has not been estabgreater improvement in the corticosteroid group at 1 lished. In some but not all studies, higher doses seem to month. Other disease-modifying anti-rheumatic drugs, be more effective than lower doses. Successfull bridge however, were warranted in 43% of the chloroquine-vs regimens involving three infusions of 1000 mg methyl-29% of the corticosteroid-treated group. prednisolone on alternate days have been reported with Long-term use: glucocorticosteroids in combination concomitant start of -penicillamine or sulphasalazine [25] and i.m. gold salts [31] , but not with azathioprine with other second-line drugs. Kirwan [3] recently pub- [26 ] . Lower doses of i.v. methylprednisolone pulses may lished a double-blind randomized trial in which a comnot be effective as bridge therapy [34, 36 ] . parison was made of the addition of prednisolone (7.5 mg daily) or placebo to other anti-rheumatic treatments in 128 early RA patients. Primary outcome variEffects on joint damage ables were related to radiological joint damage scores Long-term low-dose oral glucocorticosteroids and will be discussed later. Secondary outcomes included disease activity variables and functional capacity. After
As mentioned earlier, Kirwan [3] recently reported the 3 months, the patients in the prednisolone group had results of a double-blind randomized trial that evaluated greater reductions in an articular index (accounting primarily the effects of a fixed dose of 7.5 mg prednisofor both tender and swollen joints), pain and disability, lone daily in addition to other anti-rheumatic drugs on the progression of joint damage. The trial was designed but not in the acute-phase response. In the remainder after re-evaluation of the earlier ERC and MRC trials early RA has already been described in an earlier section of this paper where we discussed the effects of this [37] . Although not generally recognized at the time of publication, the earlier prednisolone trial [16, 17] combination treatment on indices of disease activity. Radiological scores on the progression of joint damage seemed to suggest that glucocorticosteroids could retard structural joint damage as assessed by radiological were included in the secondary end points of this trial. Radiographs of hands and feet were scored for joint scores. Kirwan included 128 patients with early disease in the study. The Larsen score was used to evaluate the space narrowing and erosions according to van der Heijden's modification of Sharp's method. The authors progression of joint damage in the hands after 1 and 2 yr. Two primary end points were defined: the mean report the median and ranges of progression of the scores after 28, 56 and 80 weeks. After 80 weeks, progression in the ( log-transformed) Larsen scores and the development of erosions on hands that had no progression scores could be calculated for 121 of 155 randomized patients. In the combined treatment group, erosions at baseline. After 2 yr, the Larsen score increased by a mean of 0.72 unit in the prednisolone the progression of erosions was less than in the sulphasalazine alone group. At week 80, the median total progroup and by 5.37 units in the placebo group (P = 0.004 for the difference between the two groups). In the gression score was 4 in the combined treatment group and 12 in the sulphasalazine alone group (P = 0.01). prednisolone group, erosions developed in 22.1% of initially normal hands, and in 45.6% in the placebo Differences in scores for erosions were more marked than for joint space narrowing. The results of this study group (P = 0.007). The authors conclude that in patients with early active RA, prednisolone (7.5 mg daily) given seem to suggest that the combination used (initial highdose prednisolone, methotrexate and sulphasalazine) is for 2 yr reduces the rate of radiologically detected progression of disease, despite the lack of a sustained effect associated with less progression of joint damage than treatment with sulphasalazine alone, although again on indices of disease activity. In our view, the findings of this study are certainly very interesting. Some points conclusions are based on only~80% of randomized patients. This beneficial effect may be due to either the of concern, however, need to be expressed. Firstly, the data collection in this trial was incomplete and the addition of methotrexate, of prednisolone or the combination of both to sulphasalazine. Circumstantial evidconclusions are based on only~80% of the randomized patients. Secondly, the placebo group included patients ence suggests that the inclusion of prednisolone in this treatment regimen is the most important factor. First, with more severe disease according to several baseline characteristics. Although the differences between the the clinical advantages experienced by the patients in the combination treatment group disappeared after the two groups were not statistically significant, an influence on the results cannot be excluded. Thirdly, we find it gradual discontinuation of prednisolone. Second, other studies evaluating the potential advantages of the comdifficult to interpret the second primary end point in a clinically meaningful way. In this study, one patient can bination of sulphasalazine and methotrexate in early RA do not suggest an important beneficial effect of this be part of two groups at the same time: one hand developing erosions and the other not! It would have combination on the progression of joint damage [39] . been more relevant to evaluate the proportion of patients who had become erosive instead of the proportion of Toxicity of glucocorticosteroids hands. In this issue, Hickling et al. [38] present the data of an additional follow-up study of 1 yr after discontinu-
The toxicity of glucocorticosteroids is well known. In general, adverse effects are more frequent and more ation of prednisolone or placebo in a double-blinded fashion. Unfortunately, adjustments had to be made to severe with higher doses and with longer periods of treatment. the raw data, as changes in reader sensitivity had occurred in comparison with the original trial [3] .
Toxicity in general Surprisingly, more correction was needed for the placebo then the prednisolone group. The mean Larsen score
The relative safety of low-dose glucocorticosteroid treatment was documented in a well-written review by increased both after discontinuation of placebo and prednisolone. However, the advantage of the prednisoCaldwell and Furst in 1991 [40] . They distinguish between adverse effects that probably occur only with lone-treated patients over the placebo group was maintained 1 yr after discontinuation of the drug. Because high-dose (>10 mg prednisolone daily) glucocorticosteroids and adverse effects that definitely or probably of the methodological issues that we mentioned in relation to both studies, firm conclusions cannot be occur also with low-dose treatment. A slightly adapted summarizing table is presented here ( Table 2) . Shortreached. Although promising, the results need to be confirmed in another study before we can recommend term, high-dose glucocorticosteroid treatment, as studied by Boers et al., may also be relatively safe. The long-term treatment with a fixed dose of prednisolone for all patients with early, active RA.
76 patients who used high doses of prednisolone in their study experienced no serious side-effects [4] . In a retroShort-term high-dose oral glucocorticosteroids spective study of 50 patients given 1000 mg methylprednisolone i.v. pulse therapy on three alternate days, The design of the study by Boers et al. [4] comparing combined step-down high-dose prednisolone, methofrequent (>5 patients) short-term complications were: rise in diastolic blood pressure (>10 mmHg), hypertrexate and sulphasalazine with sulphasalazine alone in aAdapted from Caldwell and Furst [40] . bLow dose defined as 10 mg prednisolone daily or less. cEspecially in combination with non-steroidal anti-inflammatory drugs.
glycaemia or glycosuria, facial flushing, headache, bitter bone-active drugs, bone mineral density decreased substantially. The effects on bone were present despite taste, vertigo, palpitations or tachycardia. In these beneficial effects on functional capacity. After discontinpatients, possible long-term complications that were not uation of the glucocorticosteroid treatment, this negative infrequently seen were peptic ulceration, moon face, effect appeared to be reversible for the greatest part cataract, osteoporosis, purpura and skin atrophy, pre- [43] . Reversibility of glucocorticosteroid-induced bone senting within a mean follow-up of 3.8 yr. Many of loss has also been demonstrated after cure of Cushing's these patients received more than one i.v. methylprednisyndrome or disease [44] . Other recent studies which solone pulse, while the majority were also on oral used calcium supplements in the glucocorticosteroidprednisone. Therefore, it remains difficult to attribute treated patients have not shown similar deleterious these complications to i.v. pulses that sometimes had effects, even with initially higher dosed regimens [4, 18] . been given years previously [21] .
All studies have limited themselves to relatively Glucocorticosteroid-induced osteoporosis short-term studies. The long-term effects of prolonged ( low-dose) glucocorticosteroid treatment are not and Whether low-dose glucocorticosteroid treatment is probably will not be studied in randomized trials. The associated with increased bone loss and the development available data from other types of studies indicate that of osteoporosis has been much debated. Two recent long-term low-dose use of glucocorticosteroids is probarticles illustrate the controversy nicely. In their review, ably associated with an increased risk of osteoporosis Deodhar and Woolf [41] conclude that the use of oral and related fractures [41, 45] . glucocorticosteroids in a dose of 5 mg prednisone daily Several drugs are available to prevent glucocorticoor more is a risk factor for the development of osteoporsteroid-induced bone loss. Calcitriol and cyclical osis in RA. In contrast, Verhoeven and Boers [42] , in etidronate have been proven effective in doubletheir meta-analysis, conclude that the use of glucocortblind randomized controlled trials [46] [47] [48] [49] . More data icosteroids by RA patients is probably not associated on different bisphosphonates may be expected shortly. with clinically important bone loss. Certainly, this topic
The best strategy for employing these drugs remains to remains controversial. At this moment, there is still only be determined, however. one double-blind randomized trial that evaluates the effects on bone mineral density of unopposed glucocortConclusions icosteroid treatment in patients with active RA. After 20 weeks treatment with initially 10 mg prednisone and Oral glucocorticosteroids in doses of 7.5 mg prednisolone daily or more effectively reduce disease activity in without concomitant calcium supplementation or other 
